Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology Guideline
No Thumbnail Available
Authors
Kulasekararaj, Austin
Cavenagh, Jamie
Dokal, Inderjeet
Foukaneli, Theodora
Gandhi, Shreyans
Garg, Mamta
Griffin, Morag
Hillmen, Peter
Ireland, Robin
Killick, Sally
Check for full-text access
Issue Date
2024
Type
Article
Language
Keywords
Alternative Title
Abstract
Pancytopenia with hypocellular bone marrow is the hallmark of aplastic anaemia (AA) and the diagnosis is confirmed after careful evaluation, following exclusion of alternate diagnosis including hypoplastic myelodysplastic syndromes. Emerging use of molecular cyto-genomics is helpful in delineating immune mediated AA from inherited bone marrow failures (IBMF). Camitta criteria is used to assess disease severity, which along with age and availability of human leucocyte antigen compatible donor are determinants for therapeutic decisions. Supportive care with blood and platelet transfusion support, along with anti-microbial prophylaxis and prompt management of opportunistic infections remain key throughout the disease course. The standard first-line treatment for newly diagnosed acquired severe/very severe AA patients is horse anti-thymocyte globulin and ciclosporin-based immunosuppressive therapy (IST) with eltrombopag or allogeneic haemopoietic stem cell transplant (HSCT) from a matched sibling donor. Unrelated donor HSCT in adults should be considered after lack of response to IST, and up front for young adults with severe infections and a readily available matched unrelated donor. Management of IBMF, AA in pregnancy and in elderly require special attention. In view of the rarity of AA and complexity of management, appropriate discussion in multidisciplinary meetings and involvement of expert centres is strongly recommended to improve patient outcomes.
Description
Citation
Publisher
License
Journal
British Journal of Haematology
Volume
204
Issue
3